1
|
A simulation study on using 252Cf for the treatment of esophagus tumor in human phantom. EJNMMI Phys 2020; 7:71. [PMID: 33270176 PMCID: PMC7714864 DOI: 10.1186/s40658-020-00341-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 11/24/2020] [Indexed: 12/24/2022] Open
Abstract
Due to the sensitivity of this tissue, and the potential for metastasis of its cancer as well, finding accurate methods to be employed for the treatment of esophagus tumors is of especial interest for the researchers. The present study deals with a Monte Carlo simulation of 252Cf neutron brachytherapy for treating these tumors using MCNPX (Version 2.6.0) code. The widely accepted AAPM TG-43 protocol has been used to benchmark the simulated source and to examine the accuracy of the modeling. The MIRD human phantom has been used for dose evaluation in the mentioned tumor and in the surrounding normal tissues as well. To decrease the dose delivered to the healthy tissue, using appropriate shields has been proposed. Through dosimetric calculations for several candidates, Pt-Ir 10% with a thickness of 1 cm has been selected as the optimized shield. The depth-dose results as well as the isodose curves corresponding to the presence of the shielded 252Cf neutron source in the center of the simulated tumor offer this source as an appropriate candidate to be used for the treatment of the esophagus tumors and sparing normal tissues. For a suggested clinical condition of positioning the source inside the esophagus, the damage to the first depth in spine can be avoided by managing the treatment time.
Collapse
|
2
|
Redler G, Templeton A, Zhen H, Turian J, Bernard D, Chu JC, Griem KL, Liao Y. Dosimetric effects of saline- versus water-filled balloon applicators for IORT using the model S700 electronic brachytherapy source. Brachytherapy 2018; 17:500-505. [DOI: 10.1016/j.brachy.2017.11.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 11/03/2017] [Accepted: 11/03/2017] [Indexed: 12/19/2022]
|
3
|
Nath R, Rivard MJ, DeWerd LA, Dezarn WA, Thompson Heaton H, Ibbott GS, Meigooni AS, Ouhib Z, Rusch TW, Siebert FA, Venselaar JLM. Guidelines by the AAPM and GEC-ESTRO on the use of innovative brachytherapy devices and applications: Report of Task Group 167. Med Phys 2017; 43:3178-3205. [PMID: 27277063 DOI: 10.1118/1.4951734] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Although a multicenter, Phase III, prospective, randomized trial is the gold standard for evidence-based medicine, it is rarely used in the evaluation of innovative devices because of many practical and ethical reasons. It is usually sufficient to compare the dose distributions and dose rates for determining the equivalence of the innovative treatment modality to an existing one. Thus, quantitative evaluation of the dosimetric characteristics of innovative radiotherapy devices or applications is a critical part in which physicists should be actively involved. The physicist's role, along with physician colleagues, in this process is highlighted for innovative brachytherapy devices and applications and includes evaluation of (1) dosimetric considerations for clinical implementation (including calibrations, dose calculations, and radiobiological aspects) to comply with existing societal dosimetric prerequisites for sources in routine clinical use, (2) risks and benefits from a regulatory and safety perspective, and (3) resource assessment and preparedness. Further, it is suggested that any developed calibration methods be traceable to a primary standards dosimetry laboratory (PSDL) such as the National Institute of Standards and Technology in the U.S. or to other PSDLs located elsewhere such as in Europe. Clinical users should follow standards as approved by their country's regulatory agencies that approved such a brachytherapy device. Integration of this system into the medical source calibration infrastructure of secondary standard dosimetry laboratories such as the Accredited Dosimetry Calibration Laboratories in the U.S. is encouraged before a source is introduced into widespread routine clinical use. The American Association of Physicists in Medicine and the Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) have developed guidelines for the safe and consistent application of brachytherapy using innovative devices and applications. The current report covers regulatory approvals, calibration, dose calculations, radiobiological issues, and overall safety concerns that should be addressed during the commissioning stage preceding clinical use. These guidelines are based on review of requirements of the U.S. Nuclear Regulatory Commission, U.S. Department of Transportation, International Electrotechnical Commission Medical Electrical Equipment Standard 60601, U.S. Food and Drug Administration, European Commission for CE Marking (Conformité Européenne), and institutional review boards and radiation safety committees.
Collapse
Affiliation(s)
- Ravinder Nath
- Department of Therapeutic Radiology, School of Medicine, Yale University, New Haven, Connecticut 06510
| | - Mark J Rivard
- Department of Radiation Oncology, School of Medicine, Tufts University, Boston, Massachusetts 02111
| | - Larry A DeWerd
- Accredited Dosimetry and Calibration Laboratory, University of Wisconsin, Madison, Wisconsin 53706
| | - William A Dezarn
- Department of Radiation Oncology, School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157
| | | | - Geoffrey S Ibbott
- Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030
| | - Ali S Meigooni
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89169
| | - Zoubir Ouhib
- Radiation Oncology, Lynn Regional Cancer Center, Delray Beach, Florida 33484
| | - Thomas W Rusch
- Xoft, Inc., A Subsidiary of iCAD, Inc., San Jose, California 95134
| | - Frank-André Siebert
- Clinic of Radiotherapy, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel 24105, Germany
| | - Jack L M Venselaar
- Department of Medical Physics and Engineering, Instituut Verbeeten, Tilburg LA 5000, The Netherlands
| |
Collapse
|
4
|
Kirisits C, Rivard MJ, Baltas D, Ballester F, De Brabandere M, van der Laarse R, Niatsetski Y, Papagiannis P, Hellebust TP, Perez-Calatayud J, Tanderup K, Venselaar JLM, Siebert FA. Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM. Radiother Oncol 2013; 110:199-212. [PMID: 24299968 PMCID: PMC3969715 DOI: 10.1016/j.radonc.2013.11.002] [Citation(s) in RCA: 230] [Impact Index Per Article: 20.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 10/30/2013] [Accepted: 11/04/2013] [Indexed: 11/21/2022]
Abstract
Background and purpose A substantial reduction of uncertainties in clinical brachytherapy should result in improved outcome in terms of increased local control and reduced side effects. Types of uncertainties have to be identified, grouped, and quantified. Methods A detailed literature review was performed to identify uncertainty components and their relative importance to the combined overall uncertainty. Results Very few components (e.g., source strength and afterloader timer) are independent of clinical disease site and location of administered dose. While the influence of medium on dose calculation can be substantial for low energy sources or non-deeply seated implants, the influence of medium is of minor importance for high-energy sources in the pelvic region. The level of uncertainties due to target, organ, applicator, and/or source movement in relation to the geometry assumed for treatment planning is highly dependent on fractionation and the level of image guided adaptive treatment. Most studies to date report the results in a manner that allows no direct reproduction and further comparison with other studies. Often, no distinction is made between variations, uncertainties, and errors or mistakes. The literature review facilitated the drafting of recommendations for uniform uncertainty reporting in clinical BT, which are also provided. The recommended comprehensive uncertainty investigations are key to obtain a general impression of uncertainties, and may help to identify elements of the brachytherapy treatment process that need improvement in terms of diminishing their dosimetric uncertainties. It is recommended to present data on the analyzed parameters (distance shifts, volume changes, source or applicator position, etc.), and also their influence on absorbed dose for clinically-relevant dose parameters (e.g., target parameters such as D90 or OAR doses). Publications on brachytherapy should include a statement of total dose uncertainty for the entire treatment course, taking into account the fractionation schedule and level of image guidance for adaptation. Conclusions This report on brachytherapy clinical uncertainties represents a working project developed by the Brachytherapy Physics Quality Assurances System (BRAPHYQS) subcommittee to the Physics Committee within GEC-ESTRO. Further, this report has been reviewed and approved by the American Association of Physicists in Medicine.
Collapse
Affiliation(s)
- Christian Kirisits
- Department of Radiotherapy, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria.
| | - Mark J Rivard
- Department of Radiation Oncology, Tufts University School of Medicine, Boston, USA
| | - Dimos Baltas
- Department of Medical Physics & Engineering, Sana Klinikum Offenbach, Germany
| | | | | | | | | | | | - Taran Paulsen Hellebust
- Department of Medical Physics, Oslo University Hospital, The Radium Hospital, Oslo, Norway; Department of Physics, University of Oslo, Oslo, Norway
| | | | | | - Jack L M Venselaar
- Department of Medical Physics and Engineering, Instituut Verbeeten, Tilburg, The Netherlands
| | | |
Collapse
|
5
|
Dose correction in lung for HDR breast brachytherapy. J Contemp Brachytherapy 2013; 4:106-10. [PMID: 23349652 PMCID: PMC3552632 DOI: 10.5114/jcb.2012.29367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 05/16/2012] [Accepted: 06/06/2012] [Indexed: 11/17/2022] Open
Abstract
Purpose To evaluate the dosimetric impact of lung tissue in Ir-192 APBI. Material and methods In a 40 × 40 × 40 cm3 water tank, an Accelerated Partial Breast Irradiation (APBI) brachytherapy balloon inflated to 4 cm diameter was situated directly below the center of a 30 × 30 × 1 cm3 solid water slab. Nine cm of solid water was stacked above the 1 cm base. A parallel plate ion chamber was centered above the base and ionization current measurements were taken from the central HDR source dwell position for channels 1, 2, 3 and 5 of the balloon. Additional ionization data was acquired in the 9 cm stack at 1 cm increments. A comparable data set was also measured after replacing the 9 cm solid water stack with cork slabs. The ratios of measurements in the two phantoms were calculated and compared to predicted results of a commercial treatment planning system. Results Lower dose was measured in the cork within 1 cm of the cork/solid water interface possibly due to backscatter effects. Higher dose was measured beyond 1 cm from the cork/solid water interface, increasing with path length up to 15% at 9 cm depth in cork. The treatment planning system did not predict either dose effect. Conclusions This study investigates the dosimetry of low density material when the breast is treated with Ir-192 brachytherapy. HDR dose from Ir-192 in a cork media is shown to be significantly different than in unit density media. These dose differences are not predicted in most commercial brachytherapy planning systems. Empirical models based on measurements could be used to estimate lung dose associated with HDR breast brachytherapy.
Collapse
|
6
|
Sung W, Kim S, Kim JI, Lee JG, Shin YJ, Jung JY, Ye SJ. Dosimetric perturbations due to an implanted cardiac pacemaker in MammoSite® treatment. Med Phys 2012; 39:6185-91. [DOI: 10.1118/1.4752088] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
|
7
|
Pacemaker/implantable cardioverter–defibrillator dose in balloon high-dose-rate brachytherapy for breast cancer treatment. Brachytherapy 2012; 11:380-6. [DOI: 10.1016/j.brachy.2012.01.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Revised: 12/30/2011] [Accepted: 01/02/2012] [Indexed: 01/01/2023]
|
8
|
Bensaleh S, Bezak E. The impact of uncertainties associated with MammoSite brachytherapy on the dose distribution in the breast. J Appl Clin Med Phys 2011; 12:3464. [PMID: 22089003 PMCID: PMC5718740 DOI: 10.1120/jacmp.v12i4.3464] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2010] [Revised: 05/12/2011] [Accepted: 05/17/2011] [Indexed: 01/19/2023] Open
Abstract
The MammoSite radiation therapy system is a novel technique for treatment of patients with early-stage breast cancer. It was developed to overcome the longer schedules associated with external-beam radiation therapy. It consists of a small balloon (4 cm in diameter) connected to an inflation channel and a catheter for the passage of a high dose rate 192Ir brachytherapy source. The device is placed into the tumor resection cavity and inflated with a mixture of saline and radiographic contrast agent to a size that fills the cavity. A high dose rate 192Ir source is driven into the balloon center using a remote afterloader to deliver the prescribed dose at a point 1 cm away from the balloon surface. There are several uncertainties that affect the dose distribution in the MammoSite brachytherapy. They include source position deviation, balloon deformation, and the concentration of the contrast medium inside the balloon. The purpose of this study is to investigate the extent of the dose perturbation for various concentrations of the contrast medium in a MammoSite balloon using Monte Carlo simulations and thermoluminescent dosimetry. This study also combines the impact of these uncertainties on the MammoSite treatment efficacy. The current study demonstrates that the combined uncertainties associated with the MammoSite brachytherapy technique--up to the value of 2 mm balloon deformation, 1 mm source deviation, and 15% contrast concentration--have no impact on the tumor control probability.
Collapse
Affiliation(s)
- Saleh Bensaleh
- School of Chemistry & Physics, University of Adelaide, South Australia 5005, Australia
| | | |
Collapse
|
9
|
Lim YK, Hwang UJ, Shin D, Kim DW, Kwak J, Yoon M, Lee DH, Lee SB, Lee SY, Park SY, Pyo HR. Proton Range Uncertainty Due to Bone Cement Injected Into the Vertebra in Radiation Therapy Planning. Med Dosim 2011; 36:299-305. [DOI: 10.1016/j.meddos.2010.05.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2010] [Accepted: 05/27/2010] [Indexed: 10/18/2022]
|
10
|
Dose reduction study in vaginal balloon packing filled with contrast for HDR brachytherapy treatment. Int J Radiat Oncol Biol Phys 2010; 80:1263-7. [PMID: 20950949 DOI: 10.1016/j.ijrobp.2010.08.033] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Revised: 08/03/2010] [Accepted: 08/17/2010] [Indexed: 11/21/2022]
Abstract
PURPOSE Vaginal balloon packing is a means to displace organs at risk during high dose rate brachytherapy of the uterine cervix. We tested the hypothesis that contrast-filled vaginal balloon packing reduces radiation dose to organs at risk, such as the bladder and rectum, in comparison to water- or air-filled balloons. METHODS AND MATERIALS In a phantom study, semispherical vaginal packing balloons were filled with air, saline solution, and contrast agents. A high dose rate iridium-192 source was placed on the anterior surface of the balloon, and the diode detector was placed on the posterior surface. Dose ratios were taken with each material in the balloon. Monte Carlo (MC) simulations, by use of the MC computer program DOSXYZnrc, were performed to study dose reduction vs. balloon size and contrast material, including commercially available iodine- and gadolinium-based contrast agents. RESULTS Measured dose ratios on the phantom with the balloon radius of 3.4 cm were 0.922 ± 0.002 for contrast/saline solution and 0.808 ± 0.001 for contrast/air. The corresponding ratios by MC simulations were 0.895 ± 0.010 and 0.781 ± 0.010. The iodine concentration in the contrast was 23.3% by weight. The dose reduction of contrast-filled balloon ranges from 6% to 15% compared with water-filled balloon and 11% to 26% compared with air-filled balloon, with a balloon size range between 1.4 and 3.8 cm, and iodine concentration in contrast of 24.9%. The dose reduction was proportional to the contrast agent concentration. The gadolinium-based contrast agents showed less dose reduction because of much lower concentrations in their solutions. CONCLUSIONS The dose to the posterior wall of the bladder and the anterior wall of the rectum can be reduced if the vaginal balloon is filled with contrast agent in comparison to vaginal balloons filled with saline solution or air.
Collapse
|
11
|
Cazeca MJ, Medich DC, Munro JJ. Effects of breast-air and breast-lung interfaces on the dose rate at the planning target volume of a MammoSite®
catheter for Yb-169 and Ir-192 HDR sources. Med Phys 2010; 37:4038-45. [DOI: 10.1118/1.3458720] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
12
|
Bensaleh S, Bezak E. Investigation of source position uncertainties & balloon deformation in MammoSite brachytherapy on treatment effectiveness. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE 2010; 33:35-44. [PMID: 20300986 DOI: 10.1007/s13246-010-0008-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2009] [Accepted: 02/17/2010] [Indexed: 11/26/2022]
Abstract
The MammoSite breast high dose rate brachytherapy is used in treatment of early-stage breast cancer. The tumour bed volume is irradiated with high dose per fraction in a relatively small number of fractions. Uncertainties in the source positioning and MammoSite balloon deformation will alter the prescribed dose within the treated volume. They may also expose the normal tissues in balloon proximity to excessive dose. The purpose of this work is to explore the impact of these two uncertainties on the MammoSite dose distribution in the breast using dose volume histograms and Monte Carlo simulations. The Lyman-Kutcher and relative seriality models were employed to estimate the normal tissues complications associated with the MammoSite dose distributions. The tumour control probability was calculated using the Poisson model. This study gives low probabilities for developing heart and lung complications. The probability of complications of the skin and normal breast tissues depends on the location of the source inside the balloon and the volume receiving high dose. Incorrect source position and balloon deformation had significant effect on the prescribed dose within the treated volume. A 4 mm balloon deformation resulted in reduction of the tumour control probability by 24%. Monte Carlo calculations using EGSnrc showed that a deviation of the source by 1 mm caused approximately 7% dose reduction in the treated target volume at 1 cm from the balloon surface. In conclusion, accurate positioning of the (192)Ir source at the balloon centre and minimal balloon deformation are critical for proper dose delivery with the MammoSite brachytherapy applicator. On the basis of this study, we suggest that the MammoSite treatment protocols should allow for a balloon deformation of < or = 2 mm and a maximum source deviation of < or = 1 mm.
Collapse
Affiliation(s)
- S Bensaleh
- Department of Medical Physics, Royal Adelaide Hospital, Adelaide, Australia.
| | | |
Collapse
|
13
|
Oh S, Scott J, Shin DH, Suh TS, Kim S. Measurements of dose discrepancies due to inhomogeneities and radiographic contrast in balloon catheter brachytherapy. Med Phys 2009; 36:3945-54. [PMID: 19810467 DOI: 10.1118/1.3183497] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Recently, a device called MammoSite, consisting of a balloon and a catheter, was developed to perform partial-breast irradiation using a high-dose-rate (HDR) brachytherapy unit with ease and reproducibility. However, the actual dose to the skin does not agree well with the calculated dose by the treatment planning system because of the difference between the calculation condition and the real treatment condition (i.e., homogeneous water and full scatter condition vs contrast solution and lack of full scatter condition). In this study, the authors experimentally estimated dose discrepancies due to contrast and lack of full scatter in breast HDR brachytherapy with MammoSite. Using metal-oxide-semiconductor field-effect transistor detectors and a breast phantom, the dose discrepancies between the calculation and the treatment conditions were measured according to contrast concentration (10% and 20% volume ratios), balloon size (35 and 60 cm3), and source to detector distance ranging from 25 to 50 mm. The source was an Ir-192 isotope from Nucletron HDR unit. The dose discrepancies from the calculation condition due to both contrast and lack of full scatter combined ranged from about -1.4 +/- 2.5% to -18.2 +/- 2.0% in the studied cases (error bound is in two sided confidence interval of 80% based on Student's t distribution). In all cases, the effect of lack of full scatter was dominant to that of contrast and significant dose discrepancies existed between the calculation and the real treatment conditions, indicating that the actual skin dose is less than that which is currently calculated.
Collapse
Affiliation(s)
- Seungjong Oh
- Department of Biomedical Engineering, The Catholic University of Korea, Seoul 137-701, Korea
| | | | | | | | | |
Collapse
|
14
|
Poon E, Verhaegen F. A CT-based analytical dose calculation method for HDR I192r brachytherapy. Med Phys 2009; 36:3982-94. [DOI: 10.1118/1.3184695] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
15
|
Bensaleh S, Bezak E, Borg M. Review of MammoSite brachytherapy: advantages, disadvantages and clinical outcomes. Acta Oncol 2009; 48:487-94. [PMID: 19031175 DOI: 10.1080/02841860802537916] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND The MammoSite radiotherapy system is an alternative treatment option for patients with early-stage breast cancer to overcome the longer schedules associated with external beam radiation therapy. The device is placed inside the breast surgical cavity and inflated with a combination of saline and radiographic contrast to completely fill the cavity. The treatment schedule for the MammoSite monotherapy is 34 Gy delivered in 10 fractions at 1.0 cm from the balloon surface with a minimum of 6 hours between fractions on the same day. MATERIAL AND METHODS This review article presents the advantages, disadvantages, uncertainties and clinical outcomes associated with the MammoSite brachytherapy (MSB). RESULTS Potential advantages of MSB are: high localised dose with rapid falloff for normal tissue sparing, minimum delay between surgery and RT, catheter moves with breast, improved local control, no exposure to staff, likely side-effects reduction and potential cost/time saving (e.g. for country patients). The optimal cosmetic results depend on the balloon-to-skin distance. Good-to-excellent cosmetic results are achieved for patients with balloon-skin spacing of > or =7 mm. There have been very few published data regarding the long term tumour control and cosmesis associated with the MSB. The available data on the local control achieved with the MSB were comparable with other accelerated partial breast irradiation techniques. The contrast medium inside the balloon causes dose reduction at the prescription point. Current brachytherapy treatment planning systems (BTPS) do not take into account the increased photon attenuation due to high Z of contrast. Some BTPS predicted up to 10% higher dose near the balloon surface compared with Monte Carlo calculations using various contrast concentrations (5-25%). CONCLUSION Initial clinical results have shown that the MammoSite device could be used as a sole radiation treatment for selected patients with early stage breast cancer providing good local control, minimal complication rate and excellent cosmesis.
Collapse
|
16
|
Strauss JB, Dickler A. Accelerated partial breast irradiation utilizing balloon brachytherapy techniques. Radiother Oncol 2009; 91:157-65. [DOI: 10.1016/j.radonc.2008.12.014] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2007] [Revised: 12/20/2008] [Accepted: 12/25/2008] [Indexed: 10/21/2022]
|
17
|
Baltas D, Lymperopoulou G, Zamboglou N. On the use of HDR 60Co source with the MammoSite radiation therapy system. Med Phys 2009; 35:5263-8. [PMID: 19175085 DOI: 10.1118/1.3002312] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
This work summarizes Monte Carlo results in order to evaluate the potential of using HDR 60Co sources in accelerated partial breast irradiation (APBI) with the MammoSite applicator. Simulations have been performed using the MCNP5 Monte Carlo Code, in simple geometries comprised of two concentric spheres; the internal consisting of selected concentrations, C, of a radiographic contrast solution in water (Omnipaque 300) to simulate the MammoSite balloon and the external consisting of water to simulate surrounding tissue. The magnitude of the perturbation of delivered dose due to the radiographic contrast medium used in the MammoSite applicator is calculated. At the very close vicinity of the balloon surface, a dose build-up region is observed, which leads to a dose overestimation by the treatment planning system (TPS) which depends on Omnipaque 300 solution concentration (and is in order of 2.3%, 3.0%, and 4.5%, respectively, at 1 mm away from the balloon - water interface, for C=10%, 15%, and 20%). However, dose overestimation by the TPS is minimal for points lying at the prescription distance (d=1 cm) or beyond, for all simulated concentrations and radii of MammoSite balloon. An analytical estimation of the integral dose outside the CTV in the simple geometries simulated shows that dose to the breast for MammoSite applications is expected to be comparable using HDR 60Co and 192Ir sources, and higher than that for 169Yb. The higher enegies of 60Co sources result to approximately twice radiation protection requirements as compared to 169Ir sources. However, they allow for more accurate dosimetry calculation with currently used treatment planning algorithms for 60Co sources, compared to 169Ir.
Collapse
Affiliation(s)
- D Baltas
- Department of Medical Physics & Engineering, Strahlenklinik, Klinikum Offenbach GmbH, Offenbach am Main, Germany
| | | | | |
Collapse
|
18
|
Choi CH, Ye SJ, Parsai EI, Shen S, Meredith R, Brezovich IA, Ove R. Dose optimization of breast balloon brachytherapy using a stepping 192Ir HDR source. J Appl Clin Med Phys 2009; 10:90-102. [PMID: 19223839 PMCID: PMC5720501 DOI: 10.1120/jacmp.v10i1.2903] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2008] [Revised: 11/03/2008] [Accepted: 11/10/2008] [Indexed: 11/23/2022] Open
Abstract
To develop dose optimization schemes of breast balloon brachytherapy using a stepping of Ir192 HDR source. There is a considerable underdosage (11%–13%) of PTV due to anisotropy of a stationary source in breast balloon brachytherapy. We improved the PTV coverage by varying multiple dwell positions and weights. We assumed that the diameter of spherical balloons varied from 4.0 cm to 5.0 cm, that the PTV was a 1‐cm thick spherical shell over the balloon (reduced by the small portion occupied by the catheter path), and that the number of dwell positions varied from 2 to 13 with 0.25‐cm steps, oriented symmetrically with respect to the balloon center. By assuming that the perfect PTV coverage can be achieved by spherical dose distributions from an isotropic source, we developed an optimization program to minimize two objective functions defined as: (1) the number of PTV‐voxels having more than 10% difference between optimized doses and spherical doses, and (2) the difference between optimized doses and spherical doses per PTV‐voxel. The optimal PTV coverage occurred when applying 8–11 dwell positions with weights determined by the optimization scheme. Since the optimization yields ellipsoidal isodose distributions along the catheter, there is relative skin sparing for cases with source movement approximately tangent to the skin. We also verified the optimization in CT‐based treatment planning systems. Our volumetric dose optimization for PTV coverage showed close agreement to linear or multiple‐points optimization results from the literature. The optimization scheme provides a simple and practical solution applicable to the clinic. PACS number: 87.55.de
Collapse
Affiliation(s)
- Chang Hyun Choi
- Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
| | - Sung-Joon Ye
- Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
| | - E Ishmael Parsai
- Department of Radiation Oncology, Medical University of Ohio, Toledo, Ohio, U.S.A
| | - Sui Shen
- Department of Radiation Oncology, University of Alabama College of Medicine, Birmingham, Alabama, U.S.A
| | - Ruby Meredith
- Department of Radiation Oncology, University of Alabama College of Medicine, Birmingham, Alabama, U.S.A
| | - Ivan A Brezovich
- Department of Radiation Oncology, University of Alabama College of Medicine, Birmingham, Alabama, U.S.A
| | - Roger Ove
- Department of Radiation Oncology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, U.S.A
| |
Collapse
|
19
|
Zhang Z, Parsai EI, Feldmeier JJ. Three-dimensional quantitative dose reduction analysis in MammoSite balloon by Monte Carlo calculations. J Appl Clin Med Phys 2007; 8:139-151. [PMID: 18449153 PMCID: PMC5722616 DOI: 10.1120/jacmp.v8i4.2669] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2007] [Revised: 05/22/2007] [Accepted: 06/06/2007] [Indexed: 11/23/2022] Open
Abstract
Current treatment planning systems (TPSs) for partial breast irradiation using the MammoSite brachytherapy applicator (Cytyc Corporation, Marlborough, MA) often neglect the effect of inhomogeneity, leading to potential inaccuracies in dose distributions. Previous publications either have studied only a planar dose perturbation along the bisector of the source or have paid little attention to the anisotropy effect of the system. In the present study, we investigated the attenuation‐corrected radial dose and anisotropy functions in a form parallel to the updated American Association of Physicists in Medicine TG‐43 formalism. This work quantitatively delineates the inaccuracies in dose distributions in three‐dimensional space. Monte Carlo N‐particle transport code simulations in coupled photon–electron transport were used to quantify the changes in dose deposition and distribution caused by the increased attenuation coefficient of iodine‐based contrast solution. The source geometry was that of the VariSource wire model VS2000 (Varian Medical Systems, Palo Alto, CA). The concentration of the iodine‐based solution was varied from 5% to 25% by volume, a range recommended by the balloon's manufacturer. Balloon diameters of 4, 5, and 6 cm were simulated. Dose rates at the typical prescription line (1 cm away from the balloon surface) were determined for various polar angles. The computations showed that the dose rate reduction throughout the entire region of interest ranged from 0.64% for the smallest balloon diameter and contrast concentration to 6.17% for the largest balloon diameter and contrast concentration. The corrected radial dose function has a predominant influence on dose reduction, but the corrected anisotropy functions explain only the effect at the MammoSite system poles. By applying the corrected radial dose and anisotropy functions to TPSs, the attenuation effect can be reduced to the minimum. PACS number: 87.53.‐j
Collapse
Affiliation(s)
- Zhengdong Zhang
- University of Toledo, College of Medicine, Department of Radiation Oncology, Toledo, Ohio, U.S.A
| | - E Ishmael Parsai
- University of Toledo, College of Medicine, Department of Radiation Oncology, Toledo, Ohio, U.S.A
| | - John J Feldmeier
- University of Toledo, College of Medicine, Department of Radiation Oncology, Toledo, Ohio, U.S.A
| |
Collapse
|
20
|
Papagiannis P, Karaiskos P, Georgiou E, Baltas D, Lymperopoulou G, Pantelis E, Sakelliou L. On the use of high dose rate Ir192 and Yb169 sources with the MammoSite®radiation therapy system. Med Phys 2007; 34:3614-3619. [DOI: 10.1118/1.2760306] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2007] [Revised: 06/27/2007] [Accepted: 06/27/2007] [Indexed: 11/07/2022] Open
|
21
|
Choi Y, Kim JK, Lee HS, Hur WJ, Hong YS, Park S, Ahn K, Cho H. Influence of intravenous contrast agent on dose calculations of intensity modulated radiation therapy plans for head and neck cancer. Radiother Oncol 2006; 81:158-62. [PMID: 17050020 DOI: 10.1016/j.radonc.2006.09.010] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2006] [Revised: 09/19/2006] [Accepted: 09/22/2006] [Indexed: 11/22/2022]
Abstract
BACKGROUND AND PURPOSE To evaluate the effect of an intravenous contrast agent (CA) on dose calculations and its clinical significance in intensity modulated radiation therapy (IMRT) plans for head and neck cancer. MATERIALS AND METHODS Fifteen patients with head and neck cancer and involved neck nodes were enrolled. Each patient took two sets of computerized tomography (CT) in the same position before and after intravenous CA injections. Target volumes and organs at risk (OAR) were contoured on the enhanced CT, and then an IMRT plan of nine equiangular beams with a 6 MV X-ray was created. After the fusion of non-enhanced and enhanced CTs, the contours and the IMRT plan created from the enhanced CT were copied and placed to the non-enhanced CT. Doses were calculated again from the non-enhanced CT by the same IMRT plan. The radiation doses calculated from the two sets of CTs were compared with regard to planning target volumes (PTV) and the three OARs, both parotid glands and the spinal cord, by Wilcoxon's signed rank test. RESULTS The doses (maximum, mean, and the dose of 95% of PTV received (D95%)) of PTV70 and PTV59.4 calculated from the enhanced CTs were lower than those from the non-enhanced CTs (p < 0.05), but the dose differences were less than 1% compared to the doses calculated from the enhanced CTs. The doses of PTV50.4, parotid glands, and spinal cord were not significantly different between the non-enhanced and enhanced CTs. CONCLUSIONS The difference between the doses calculated from the CTs with and without CA enhancement was tolerably small, therefore using intravenous CA could be recommended for the planning CT of head and neck IMRT.
Collapse
Affiliation(s)
- Youngmin Choi
- Department of Radiation Oncology, College of Medicine, Dong-A University Hospital, Sugu, Busan, South Korea.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Kassas B, Mourtada F, Horton JL, Lane RG, Buchholz TA, Strom EA. Dose modification factors for 192Ir high-dose-rate irradiation using Monte Carlo simulation. J Appl Clin Med Phys 2006; 7:28-34. [PMID: 17533345 PMCID: PMC5722431 DOI: 10.1120/jacmp.v7i3.2293] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2006] [Revised: 05/30/2006] [Accepted: 12/31/1969] [Indexed: 11/23/2022] Open
Abstract
A recently introduced brachytherapy system for partial breast irradiation, MammoSite, consists of a balloon applicator filled with contrast solution and a catheter for insertion of an 192Ir high-dose-rate (HDR) source. In using this system, the treatment dose is typically prescribed to be delivered 1 cm from the balloon's surface. Most treatment-planning systems currently in use for brachytherapy procedures use water-based dosimetry with no correction for heterogeneity. Therefore, these systems assume that full scatter exists regardless of the amount of tissue beyond the prescription line. This assumption might not be a reasonable one, especially when the tissue beyond the prescription line is thin. In such a case, the resulting limited scatter could cause an underdose to be delivered along the prescription line. We used Monte Carlo simulations to investigate how the thickness of the tissue between the surface of the balloon and the skin or lung affected the treatment dose delivery. Calculations were based on a spherical water phantom with a diameter of 30 cm and balloons with diameters of 4 cm, 5 cm, and 6 cm. The dose modification factor is defined as the ratio of the dose rate at the typical prescription distance of 1 cm from the balloon's surface with full scatter obtained using the water phantom to the dose rate with a finite tissue thickness (from 0 cm to 10 cm) beyond the prescription line. The dose modification factor was found to be dependent on the balloon diameter and was 1.098 for the 4-cm balloon and 1.132 for the 6-cm balloon with no tissue beyond the prescription distance at the breast-skin interface. The dose modification factor at the breast-lung interface was 1.067 for the 4-cm balloon and 1.096 for the 6-cm balloon. Even 5 cm of tissue beyond the prescription distance could not result in full scatter. Thus, we found that considering the effect of diminished scatter is important to accurate dosimetry. Not accounting for the dose modification factor may result in delivering a lower dose than is prescribed.
Collapse
Affiliation(s)
- Bassel Kassas
- Radiation Oncology Department, Greater Baltimore Medical Center, Baltimore, Maryland 21204, USA.
| | | | | | | | | | | |
Collapse
|
23
|
Dickler A. The MammoSite® breast brachytherapy device: targeted delivery of breast brachytherapy. Future Oncol 2005; 1:799-804. [PMID: 16556059 DOI: 10.2217/14796694.1.6.799] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The MammoSite® breast brachytherapy device was designed to overcome the logistic difficulties presented by external beam radiation therapy and the technical difficulties of multicatheter-based interstitial brachytherapy. The device consists of a silicone balloon connected to a catheter which contains an inflation channel and a port for passage of a high-dose-rate brachytherapy source. The American Brachytherapy Society and American Society of Breast Surgeons have published partial breast irradiation patient selection guidelines. Initial reports have shown a favorable cosmetic outcome in the majority of patients. The MammoSite applicator has also been associated with minimal side effects. The NSABP B-39/RTOG 0413 trial will randomize patients to either whole breast irradiation or partial-breast irradiation consisting of interstitial brachytherapy, MammoSite brachytherapy, or 3D conformal radiation. This national randomized trial has the potential to provide a definitive answer regarding the benefits of partial-breast irradiation, and therefore lead to more women undergoing breast conserving therapy.
Collapse
Affiliation(s)
- Adam Dickler
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA.
| |
Collapse
|
24
|
Dickler A, Kirk MC, Chu J, Nguyen C. The MammoSite breast brachytherapy applicator: a review of technique and outcomes. Brachytherapy 2005; 4:130-6. [PMID: 15893266 DOI: 10.1016/j.brachy.2004.12.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2004] [Revised: 12/15/2004] [Accepted: 12/15/2004] [Indexed: 11/28/2022]
Abstract
The MammoSite breast brachytherapy device was designed to overcome the potential scheduling problems associated with external beam radiotherapy (EBRT) and the technical difficulties of multi-catheter-based interstitial brachytherapy. The device consists of a silicone balloon connected to a catheter which contains an inflation channel and a port for passage of a high-dose-rate brachytherapy source. The American Brachytherapy Society and American Society of Breast Surgeons have published partial breast irradiation (PBI) patient selection guidelines. The MammoSite applicator has been shown in two dosimetric studies to treat a comparable volume to multicatheter-based interstitial implants. The MammoSite catheter can be placed at the time of lumpectomy or in a separate procedure using ultrasound guidance. Four optimization methods have been described: the single point method, the six prescription point method (RUSH Technique), the University of Southern California Norris Cancer Center Method, and the Surface Optimization Technique. An excellent or good cosmetic outcome has been reported in 80% to 93% of patients at 1 year in most studies. Cosmetic results appear highly related to skin spacing. The MammoSite applicator has been associated with early side effects comparable with traditional breast conserving therapy. A NSABP trial will randomize patients to either whole breast irradiation or PBI consisting of interstitial brachytherapy, MammoSite brachytherapy, or 3D conformal radiation.
Collapse
Affiliation(s)
- Adam Dickler
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA.
| | | | | | | |
Collapse
|
25
|
Kirk M, Hsi WC, Dickler A, Chu J, Dowlatshahi K, Francescatti D, Nguyen C. Surface optimization technique for MammoSite breast brachytherapy applicator. Int J Radiat Oncol Biol Phys 2005; 62:366-72. [PMID: 15890576 DOI: 10.1016/j.ijrobp.2004.10.038] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2004] [Revised: 10/18/2004] [Accepted: 10/20/2004] [Indexed: 11/22/2022]
Abstract
PURPOSE We present a technique to optimize the dwell times and positions of a high-dose-rate (192)Ir source using the MammoSite breast brachytherapy applicator. The surface optimization method used multiple dwell positions and optimization points to conform the 100% isodose line to the surface of the planning target volume (PTV). METHODS AND MATERIALS The study population consisted of 20 patients treated using the MammoSite device between October 2002 and February 2004. Treatment was delivered in 10 fractions of 3.4 Gy/fraction, twice daily, with a minimum of 6 h between fractions. The treatment of each patient was planned using three optimization techniques. The dosimetric characteristics of the single-point, six-point, and surface optimization techniques were compared. RESULTS The surface optimization technique increased the PTV coverage compared with the single- and six-point methods (mean percentage of PTV receiving 100% of the prescription dose was 94%, 85%, and 91%, respectively). The surface method, single-point, and six-point method had a mean dose homogeneity index of 0.62, 0.68, and 0.63 and a mean full width at half maximum value of 189, 190, and 192 cGy/fraction, respectively. CONCLUSION The surface technique provided greater coverage of the PTV than did the single- and six-point methods. Using the FWHM method, the surface, single-, and six-point techniques resulted in equivalent dose homogeneity.
Collapse
Affiliation(s)
- Michael Kirk
- Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA.
| | | | | | | | | | | | | |
Collapse
|
26
|
Cheng CW, Mitra R, Li XA, Das IJ. Dose perturbations due to contrast medium and air in MammoSite®
treatment: An experimental and Monte Carlo study. Med Phys 2005; 32:2279-2287. [PMID: 16121583 DOI: 10.1118/1.1943827] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2004] [Revised: 04/26/2005] [Accepted: 05/04/2005] [Indexed: 11/07/2022] Open
Abstract
In the management of early breast cancer, a partial breast irradiation technique called MammoSite (Proxima Therapeutic Inc., Alpharetta, GA) has been advocated in recent years. In MammoSite, a balloon implanted at the surgical cavity during tumor excision is filled with a radio-opaque solution, and radiation is delivered via a high dose rate brachytherapy source situated at the center of the balloon. Frequently air may be introduced during placement of the balloon and/or injection of the contrast solution into the balloon. The purpose of this work is to quantify as well as to understand dose perturbations due to the presence of a high-Z contrast medium and/or an air bubble with measurements and Monte Carlo calculations. In addition, the measured dose distribution is compared with that obtained from a commercial treatment planning system (Nucletron PLATO system). For a balloon diameter of 42 mm, the dose variation as a function of distance from the balloon surface is measured for various concentrations of a radio-opaque solution (in the range 5%-25% by volume) with a small volume parallel plate ion chamber and a micro-diode detector placed perpendicular to the balloon axis. Monte Carlo simulations are performed to provide a basic understanding of the interaction mechanism and the magnitude of dose perturbation at the interface near balloon surface. Our results show that the radio-opaque concentration produces dose perturbation up to 6%. The dose perturbation occurs mostly within the distances <1 mm from the balloon surface. The Plato system that does not include heterogeneity correction may be sufficient for dose planning at distances > or = 10 mm from the balloon surface for the iodine concentrations used in the MammoSite procedures. The dose enhancement effect near the balloon surface (<1 mm) due to the higher iodine concentration is not correctly predicted by the Plato system. The dose near the balloon surface may be increased by 0.5% per cm3 of air. Monte Carlo simulation suggests that the interface effect (enhanced dose near surface) is primarily due to Compton electrons of short range (<0.5 mm). For more accurate dosimetry in MammoSite delivery, the dose perturbation due to the presence of a radio-opaque contrast medium and air bubbles should be considered in a brachytherapy planning system.
Collapse
Affiliation(s)
- C W Cheng
- Arizona Oncology Associates, 2625 N. Craycroft Road, Suite 100, Tucson, Arizona 85712, USA.
| | | | | | | |
Collapse
|
27
|
Niu H, Hsi WC, Chu JCH, Kirk MC, Kouwenhoven E. Dosimetric characteristics of the Leipzig surface applicators used in the high dose rate brachy radiotherapy. Med Phys 2005; 31:3372-7. [PMID: 15651620 DOI: 10.1118/1.1812609] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
The nucletron Leipzig applicator is designed for (HDR) 192Ir brachy radiotherapy of surface lesions. The dosimetric characteristics of this applicator were investigated using simulation method based on Monte Carlo N-particle (MCNP) code and phantom measurements. The simulation method was validated by comparing calculated dose rate distributions of nucletron microSelectron HDR 192Ir source against published data. Radiochromic films and metal-oxide-semiconductor field-effect transistor (MOSFET) detectors were used for phantom measurements. The double exposure technique, correcting the nonuniform film sensitivity, was applied in the film dosimetry. The linear fit of multiple readings with different irradiation times performed for each MOSFET detector measurement was used to obtain the dose rate of each measurement and to correct the source transit-time error. The film and MOSFET measurements have uncertainties of 3%-7% and 3%-5%, respectively. The dose rate distributions of the Leipzig applicator with 30 mm opening calculated by the validated MC method were verified by measurements of film and MOSFET detectors. Calculated two-dimensional planar dose rate distributions show similar patterns as the film measurement. MC calculated dose rate at a reference point defined at depth 5 mm on the applicator's central axis is 7% lower than the film and 3% higher than the MOSFET measurements. The dose rate of a Leipzig applicator with 30 mm opening at reference point is 0.241+/-3% cGy h(-1) U(-1). The MC calculated depth dose rates and profiles were tabulated for clinic use.
Collapse
Affiliation(s)
- Hongquan Niu
- Department of Medical Physics and Radiation Oncology, Rush University Medical Center, Chicago, Illinois 60612, USA.
| | | | | | | | | |
Collapse
|